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Background: In many resource-limited settings monitoring of
combination antiretroviral therapy (cART) is based on the current
CD4 count, with limited access to HIV RNA tests or laboratory
diagnostics. We examined whether the CD4 count slope over 6
months could provide additional prognostic information.
Methods: We analyzed data from a large multicohort study in
South Africa, where HIV RNA is routinely monitored. Adult HIV-
positive patients initiating cART between 2003 and 2010 were
included. Mortality was analyzed in Cox models; CD4 count slope
by HIV RNA level was assessed using linear mixed models.
Results: About 44,829 patients (median age: 35 years, 58% female,
median CD4 count at cART initiation: 116 cells/mm3) were followed
up for a median of 1.9 years, with 3706 deaths. Mean CD4 count
slopes per week ranged from 1.4 [95% conﬁdence interval (CI): 1.2 to
1.6] cells per cubic millimeter when HIV RNA was ,400 copies per
milliliter to 20.32 (95% CI: 20.47 to 20.18) cells per cubic milli-
meter with .100,000 copies per milliliter. The association of CD4
slope with mortality depended on current CD4 count: the adjusted
hazard ratio (aHRs) comparing a .25% increase over 6 months with
a .25% decrease was 0.68 (95% CI: 0.58 to 0.79) at ,100 cells per
cubic millimeter but 1.11 (95% CI: 0.78 to 1.58) at 201–350 cells per
cubic millimeter. In contrast, the aHR for current CD4 count, com-
paring .350 with ,100 cells per cubic millimeter, was 0.10 (95%
CI: 0.05 to 0.20).
Conclusions: Absolute CD4 count remains a strong risk for
mortality with a stable effect size over the ﬁrst 4 years of cART.
However, CD4 count slope and HIV RNA provide independently
added to the model.
Key Words: HIV, resource-limited setting, CD4 count slope,
mortality, HIV RNA, antiretroviral therapy
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BACKGROUND
Monitoring changes in CD4 T-cell lymphocyte count
(CD4 count) is a cornerstone of managing patients before
combination antiretroviral therapy (cART) initiation and
during cART. It is used for guiding timing of cART initiation
and assessing risk of opportunistic illnesses and evaluating for
possible treatment failure.1 However, CD4 count decline
before cART initiation is highly variable and depends on
multiple hosts and viral factors. For example, HIV RNA level
and current CD4 count both help to predict CD4 count
decline before cART initiation.2,3 Likewise, CD4 count
increase after starting cART is highly heterogeneous and is
also inﬂuenced by multiple factors.4–6 This mismatch between
CD4 count change and HIV RNA level limits the clinical
value of using CD4 counts as a surrogate for HIV RNA
suppression.7–9 As a result, where the resources are available,
both CD4 count and HIV RNA are typically monitored and
are used in concert for making clinical decisions.
Absolute CD4 count is valuable for patient management
because of the strong association between CD4 count and
opportunistic illness and death, prior to cART use and during
cART.10–12 Although HIV RNA value may be associated with
mortality given other variables, including CD4 count,13 it is
frequently not routinely available in resource-limited settings.
A better understanding of the information provided by routine
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CD4 count testing may help with developing prognostic tools
and provide further insight into mortality in resource-limited
settings. For example, during the pre–antiretroviral therapy
(ART) period, beyond the current CD4 count and HIV RNA
level, CD4 slope has been reported to provide additional infor-
mation regarding mortality risk.14 However, during cART, it is
unclear what additional prognostic information is provided by
the CD4 count slope beyond that of the current CD4 count. In
addition, although the association between risk of death and
CD4 count around cART initiation is well documented, it is
unclear if the effect size persists over time on cART and data
are lacking from a resource-limited setting.15,16 Thus, several
questions remain regarding CD4 count slope and survival dur-
ing cART, particularly in resource-limited settings.
We analyzed the South African cohorts from a large
multicohort collaboration with extensive longitudinal CD4 count
and HIV RNA data to assess change in CD4 count by HIV
RNA level on cART and the associations between mortality and
current CD4 count, CD4 count slope, and HIV RNA.
METHODS
Cohorts and Eligibility Criteria
The International epidemiological Databases to Evaluate
AIDS in Southern Africa (IeDEA-SA, www.iedea-sa.org) is
a collaboration of HIV treatment cohorts in southern Afri-
ca.17,18 Each cohort regularly provides data to data centers at
the Universities of Cape Town, South Africa, and Bern, Swit-
zerland, through a speciﬁc standardized data sharing system.
This study only included cohorts from South Africa, where
regular assessment of CD4 cell count and HIV RNA is part
of routine clinical care. All laboratory tests are performed by
accredited clinical laboratories.19
The included cohorts were from the Aurum Institute,
Africa Centre for Health and Population Studies, Themba
Lethu Clinic, Khayelitsha, Gugulethu, Tygerberg, and Masi-
phumelele, and represented urban, periurban, and rural
populations.20 Patients were eligible if they were HIV positive
ART naive at the time of entry into the HIV care programs,
aged $16 years and ,85 years, initiated ART between 2003
and 2010, and had at least 6 months of potential follow-up
time. In addition, we excluded women known to be pregnant
at the time of ART initiation due to potential effects of preg-
nancy on CD4 count and on ART response. Patients with no
CD4 data were excluded from analysis. All IeDEA-SA sites
obtained ethical approval from relevant local institutions
before contributing anonymized patient data to IeDEA-SA.
Definitions
Baseline characteristics (measured within 6 months
before ART initiation) included age, sex, CD4 count, HIV
RNA, calendar year of cART initiation, and cohort. Longi-
tudinal characteristics included absolute CD4 counts and HIV
RNA values during the course of ART. We stratiﬁed current
CD4 count into 4 following levels:#100, 100–200, 201–350,
.350 cells per cubic millimeter. Current CD4 count or cur-
rent HIV RNA was deﬁned as the most recent value, which
was carried forward until the next value became available for
a maximum of 180 days. We calculated CD4 count slope as
the change in CD4 count between 2 consecutive CD4 values.
The slope was expressed as the change in CD4 cells per week
or the percentage change over 6 months in 3 categories as
follows: .25% decrease, 25% decrease to 25% increase, and
.25% increase. We used a 25% increase or decrease because
the intertest variability of CD4 count measures is approxi-
mately 20%21; we referred to the ,25% decline and ,25%
increase category as “no change.” We considered HIV RNA
as suppressed (,400 copies/mL), unsuppressed ($400 cop-
ies/mL) and in 4 levels as follows: ,400, 400–999, 1000–
39,999, 50,000–100,000, and .100,000 copies per milliliter.
The cutoff of 400 copies per milliliter was used, as this was
the upper bound of the limit of detection for HIV RNA for
assays used by some of the cohorts. The 4 levels were
selected for convenience and consistency with the literature.
Immunologic failure was deﬁned as failure to achieve a CD4
count increase .50 cells per cubic millimeter by 6 months
and .100 cells per cubic millimeter by 12 months on cART.
Ascertainment of Deaths
Deaths were ascertained as per clinic protocols. To
address the underascertainment of deaths from routine clinic
data,22–25 we linked civil identiﬁcation (ID) numbers, when
available, to the South African Department of Home Affairs
vital status registry. To address incomplete data on ID num-
bers, we used inverse probability weighting to correct for
missing deaths among those deﬁned as lost to follow-
up.24,26 Brieﬂy, patients who were lost to follow-up and
who had ID numbers were upweighted to represent all
patients lost to follow-up, enabling more accurate estimates
of mortality. The weights were based on the inverse modeled
probabilities of having an ID given cohort, gender, age, and
CD4 count addressing potential differences between patients
with and without ID numbers among those lost to follow-up.
Multiple Imputation of Missing CD4 Count
and HIV RNA Values
To address gaps in CD4 count and HIV RNA data due
to missed clinic visits or laboratory values, we created
“expected visits” for any gap of more than 300 days. We then
used multiple imputation to create complete longitudinal data
for these “expected visit days” and also imputed baseline CD4
count and HIV RNA values, when missing. We created 10
imputed datasets using a specialized software package.27 The
imputation model included sex, age, CD4 count, HIV RNA,
year of cART initiation, duration on cART, and mortality.28,29
All results of our multivariable analyses are based on the
imputed datasets and were combined with Rubin rules.30
Statistical Analyses
Baseline characteristics were summarized using
medians with interquartile ranges (IQR) or proportions.
Age, CD4 count, and HIV RNA were described as continuous
and categorical variables and used as categorical variables in
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modeling. CD4 count change by HIV RNA level was
assessed using a linear mixed model. Because our primary
interest was immune reconstitution and not the initial rise in
CD4 count, we excluded CD4 counts from the ﬁrst 6 months
of cART.31 We included sex and age as ﬁxed effects and
cohort, patient, and each time interval within a given HIV
RNA category as random effects. We displayed the distribu-
tions of CD4 count slope graphically by HIV RNA level,
plotting the distribution of CD4 count slopes (cells/mm3 per
week) within each HIV RNA category. We also described the
CD4 count slope strata of .25% decrease over 6 months, no
change, and.25% increase in relation to the HIV RNA level.
Cox proportional hazards regression models were used
to assess crude and adjusted associations between baseline and
time-updated characteristics and mortality. Time was mea-
sured from the start of cART to the ﬁrst of death, loss to
follow-up, analysis closure, or 4 years on cART. Loss to
follow-up was deﬁned as at least 6 months without a visit (and
no subsequent visits) with time censored at the last clinic visit.
Analysis closure was at 6 months before database closure to
allow for full loss to follow-up assignment. For patients who
started ART but had no further contact, we added 1 day of
follow-up to allow for their inclusion in survival analyses.
All available variables were considered potential con-
founders and were included in initial multivariable models. We
examined interactions between duration on cART (split at 12
months) and all statistically signiﬁcant variables to test the
proportional hazard assumption. We also assessed for interac-
tions between current CD4 count and CD4 count slope, current
CD4 count and current HIV RNA, and CD4 count slope and sex.
The ﬁnal Cox model included statistically signiﬁcant covariates
and CD4 count, CD4 count slope, and the interaction between
current CD4 count and CD4 count slope. Stratiﬁcation by cohort
was used to adjust for potential cohort differences. We included
CD4 count slope and CD4 count in a nonlinear manner using
polynomials. The hazard by current CD4 count, CD4 count
slope, and interaction between the 2 was visualized by means of
a 3-dimensional plot. In an attempt to assess whether the added
value of CD4 count slope in the model was independent of
absolute CD4 count, or may have provided a more precise
estimate of CD4 count at the time of death, we repeated the
analysis, limiting follow-up time to 30 days after the last CD4
count. In addition, to evaluate the effect size of an association
between CD4 count slope and mortality in the absence of HIV
RNA data, we repeated the analysis without including HIV
RNA. Finally, we assessed mortality after 6 months on cART or
12 months on cART using immunologic failure at those 2 time
points as one of the covariates. For this analysis, entry occurred
at 6 or 12 months on cART and patients were censored 6 months
after entry (at 12 or 18 months on cART).
Data were analyzed using STATA 12.0 (STATA Cor-
poration, College Station, TX) and R 2.12 (The R Development
Core Team).
RESULTS
The cohorts included a total of 47,320 patients receiving
cART. Thirty-nine (0.1%) patients were excluded because their
age was,16 or.85 years at cART initiation; 547 (1.2%) were
excluded because they initiated cART before 2002 or after
2010; 660 (1.4%) were excluded because they lacked a potential
for 6 months follow-up on cART; and 1245 (2.6%) were
excluded because they were pregnant. This left a total of
44,829 patients meeting eligibility criteria. The number of
patients per cohort ranged from 517 to 16,415. Of these
patients, 26,171 (58%) were female, the median age was 35
years (IQR: 30–42), the median CD4 count at cART initiation
was 116 cells per cubic millimeter (IQR: 52–178; Table 1).
Median duration of follow-up was 1.9 (IQR: 1.2–3.0) years.
The median number of CD4 count measurements on cART
was 3 (IQR: 2–5), obtained a median of 166 (IQR: 106–196)
days apart. There were 293,192 actual CD4 count values pres-
ent and 34,463 (10%) time points with missing CD4 counts;
and 270,832 actual HIV RNA results present and 56,823 (17%)
time points with missing HIV RNA values. During follow-up,
there were 3706 (8.3%) deaths in the weighted analysis.
CD4 Count Change by HIV RNA Suppression
CD4 count increased on an average of 1.3 [95%
conﬁdence interval (CI): 1.1 to 1.5] cells per cubic millimeter
TABLE 1. Baseline Characteristics (Total Population: 44,829)
n (%) or Median (IQR)
Sex
Men 18,658 (42)
Women 26,171 (58)
Age
16-24 2771 (6)
25-34 17,833 (40)
35-44 15,419 (34)
.44 8806 (20)
CD4 count at cART initiation
Median 116 (52–178)
HIV RNA at cART initiation
Median 51,000 (13,000–170,000)
Year of cART initiation
2003 1317 (3)
2004 4614 (10)
2005 7988 (18)
2006 11,405 (25)
2007 9606 (21)
2008 6677 (15)
2009 3222 (7)
Civil identiﬁcation number present
Yes 21,033 (46)
No 23,796 (53)
Cohort
Aurum 16,415 (37)
Gugulethu 2198 (5)
Hlabisa 7411 (17)
Khayelitsha 5845 (13)
Masiphumelele 517 (1)
McCord 2791 (6)
Thembalethu 8563 (19)
Tygerberg 1089 (2)
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per week between 6 and 48 months on cART. The steepest rise
was among those with HIV RNA ,400 copies per milliliter
with 1.4 (95% CI: 1.2 to 1.6) cells per cubic millimeter per
week, followed by 0.41 (95% CI: 0.18 to 0.60) cells per cubic
millimeter per week for HIV RNA 400–1000 copies per mil-
liliter; 0 to 0.012 (95% CI: 20.17 to 0.14) cells per cubic
millimeter per week for HIV RNA of 1000–50,000 copies
per milliliter; 21.12 (95% CI: 23.6 to 1.4) cells per cubic
millimeter per week for HIV RNA 50,000–100,000 copies
per milliliter; and 20.48 (95% CI: 20.96, 0.007) cells per
cubic millimeter per week for HIV RNA .100,000 copies
per milliliter (Fig. 1).
However, even amongst individuals with evidence of
persistent HIV RNA suppression, the CD4 count response
was heterogeneous with both increases and marked decreases
in CD4 count. During the 6-month period with HIV RNA
,400 copies per milliliter, there was a decline in CD4 count
of more than 25% among 9.0% of patients compared with
such a decline among 14% of patients when HIV RNA was
400–1000 copies per milliliter, 24% of patients when HIV
RNA was 1000–50,000 copies per milliliter, and 44% of
patients when HIV RNA was .50,000 copies per milliliter.
Mortality
All-cause mortality during the 48 months of follow-up
was 4.1 per 100 person-years (95% CI: 3.9 to 4.2). Mortality
risk was associated with current CD4 count and with the slope
in CD4 count (Table 2). In assessing the proportional hazards
assumption, we found that there was no interaction between
either current CD4 count or CD4 count slope and duration on
cART (P . 0.1). We also found no interaction between sex
and CD4 count slope (P = 0.9). However, CD4 count slope
interacted with time-updated absolute CD4 count, losing
association with mortality when the time-updated CD4 count
was .200 cells per cubic millimeter (P , 0.001 from test of
interaction). This is graphically represented in Figure 2. In
multivariable modeling, we included sex, age, current CD4
count, CD4 count trend, and HIV RNA category. In this
model, compared with a 25% decline, the mortality hazard
was lower for a nondecreasing CD4 count with a current CD4
count between 100 and 200 cells per cubic millimeter (0.76,
95% CI: 0.62 to 0.94 for no change and 0.77, 95% CI: 0.63 to
0.94 for a 25% increase). Thus, the risk of dying was lower
with an increasing CD4 count, independent of current CD4
count and HIV RNA. HIV RNA level was also associated
with mortality independent of CD4 count and CD4 count
slope, with mortality hazard increasing consistently with
increasing HIV RNA level (Table 2).
When we repeated the analysis excluding HIV RNA
from the model, the effect size of the association between
CD4 count slope increased slightly as follows: for CD4 count
#100 cells per cubic millimeter with .25% decrease as the
referent group, the hazard ratio for no change was 0.65 (95%
CI: 0.55 to 0.78) and for .25% increase was 0.51 (95% CI:
0.44 to 0.60); for CD4 count 100–200 cells per cubic milli-
meter, the hazard ratios were 0.70 (95% CI: 0.57 to 0.86) and
0.65 (95% CI: 0.53 to 0.80), respectively; for CD4 counts
201–350 cells per cubic millimeter, the hazard ratios were
0.84 (95% CI: 0.56 to 1.09) and 1.0 (95% CI: 0.70 to 1.4),
respectively; and ﬁnally for CD4 counts .350 cells per cubic
millimeter, the hazard ratios were 0.87 (95% CI: 0.41 to 1.9)
and 1.2 (95% CI: 0.59 to 2.6), respectively.
To further assess the role of CD4 count trend, we
undertook an analysis censoring time 30 days after the last
CD4 count and repeating the adjusted analysis. In this
analysis, the association between CD4 count trend and
mortality remained with a slight but nonsigniﬁcant increase
in effect sizes.
We also assessed for an association between CD4 count
response/failure at 6 and 12 months and mortality. In
multivariable modeling, adjusting for current CD4 count,
current HIV RNA, sex, and age, both 6 and 12 months CD4
count response was associated independently with reduced
mortality with an adjusted hazard ratio of 0.63 (95% CI: 0.51
to 0.80, P , 0.001) for CD4 count response by 6 months and
FIGURE 1. CD4 count slope distri-
bution density by HIV RNA level. The
y axis represents density of CD4
count slopes.
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an adjusted hazard ratio of 0.37 (95% CI: 0.20 to 0.69,
P = 0.002) for CD4 count response by 12 months.
DISCUSSION
Using a large multicohort ART population with robust
mortality estimates and availability of routine laboratory
monitoring, we have demonstrated that a lower current CD4
count, CD4 count slope with .25% decline averaged over 6
months, and a higher current HIV RNA level each are inde-
pendently associated with increased mortality among people
receiving cART. Furthermore, although mortality declined
with time from cART initiation, the effect size between
CD4 count and mortality remained constant over time on
cART, consistent with a study from Northern cohorts.15 Thus,
we reconﬁrm the strong association between CD4 count and
mortality, demonstrating that it remains constant for up to 4
years on ART, and have added ﬁndings on the associations
both of current HIV RNA level and CD4 count slope in
estimating mortality hazard. In addition, patients with a poor
initial CD4 response despite virological suppression were at
an even greater hazard of death than suggested by the other
parameters, including current CD4 count.
Our ﬁndings of an association between CD4 count
slope and mortality build on the overall understanding of
mortality risk during cART, adding the independent value of
TABLE 2. Univariable and Multivariable Associations With Mortality up to 3 Years on cART
Mortality per 100 Person-Years HR P aHR P
Sex
Men 5.1 (4.8 to 5.4) Referent ,0.001 Referent 0.009
Women 3.4 (3.2 to 3.5) 0.75 (0.69 to 0.81) 0.89 (0.82 to 0.97)
Age (yrs)
16–24 3.3 (2.8 to 3.9) Referent ,0.001 Referent ,0.001
25–34 3.3 (3.1 to 3.5) 0.96 (0.80 to 1.15) 1.02 (0.85 to 1.22)
35–44 4.3 (4.0 to 4.6) 1.16 (0.97 to 1.39) 1.26 (1.05 to 1.52)
.44 5.4 (5.0 to 5.8) 1.43 (1.18 to 1.72) 1.58 (1.30 to 1.91)
Weight at ART initiation (kg)
,50 7.1 (6.6 to 7.7) Referent — Referent —
50–80 3.7 (3.5 to 3.8) 0.52 (0.48 to 0.57) 0.55 (0.50 to 0.61)
.80 2.9 (2.5 to 3.4) 0.37 (0.30 to 0.46) 0.46 (0.38 to 0.57)
Current CD4 count (cells/mm3)
#100 14 (14 to 15) Referent ,0.001 Referent ,0.001
100–200 5.0 (4.7 to 5.4) 0.32 (0.29 to 0.35) 0.38 (0.32 to 0.46)
201–350 2.5 (2.3 to 2.8) 0.15 (0.14 to 0.17) 0.18 (0.13 to 0.25)
.350 1.4 (1.2 to 1.6) 0.09 (0.07 to 0.10) 0.10 (0.05 to 0.20)
CD4 count trend*
CD4 count: ,100
.25% Decrease 30 (27 to 33) Referent ,0.001 Referent ,0.001
No change 20 (17 to 23) 0.66 (0.56 to 0.79) 0.75 (0.63 to 0.89)
.25% Increase 16 (14 to 18) 0.52 (0.45 to 0.60) 0.68 (0.58 to 0.79)
CD4 count: 100–200
.25% Decrease 8.2 (6.9 to 9.7) Referent — Referent —
No change 5.2 (4.4 to 6.0) 0.70 (0.57 to 0.86) 0.79 (0.64 to 0.98)
.25% Increase 4.3 (3.7 to 5.0) 0.65 (0.53 to 0.80) 0.79 (0.63 to 0.98)
CD4 count: 201–350
.25% Decrease 2.4 (1.8 to 3.4) Referent — Referent —
No change 2.1 (1.8 to 2.5) 0.79 (0.56 to 1.09) 0.87 (0.63 to 1.21)
.25% Increase 2.8 (2.5 to 3.2) 1.00 (0.71 to 1.43) 1.11 (0.78 to 1.58)
CD4 count: .350
.25% Decrease 0.91 (0.46 to 2.0) Referent — Referent —
No change 1.0 (0.83 to 1.3) 0.88 (0.41 to 1.88) 0.95 (0.45 to 2.03)
.25% increase 1.6 (1.3 to 1.8) 1.25 (0.60 to 2.62) 1.31 (0.63 to 2.76)
HIV RNA (copies/mL)
,400 2.8 (2.7 to 3.0) Referent ,0.001 Referent ,0.001
400–4999 3.6 (3.3 to 4.0) 1.95 (1.69 to 2.26) 1.63 (1.41 to 1.89)
5000–50,000 9.7 (8.8 to 11) 3.34 (2.94 to 3.80) 2.18 (1.92 to 2.48)
.50,000 22 (20 to 23) 6.51 (5.89 to 7.20) 3.16 (2.82 to 3.55)
*Interaction between updated CD4 count and CD4 count slope; P , 0.001.
HR, crude hazard ratio; aHR, adjusted hazard ratio.
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the CD4 count slope.22,23,32–37 The ﬁnding raises the question
of whether the CD4 count decline is a result of an ongoing
illness or whether the declining CD4 count predisposes to
a potentially life-threatening illness. Another possibility is
that the CD4 count slope provides a better measure of the
true CD4 count at the time of an event. However, our ﬁnding
of association between CD4 count slope and mortality, even
when limiting follow-up to 30 days after the last CD4 count,
makes this a less likely explanation. Whether this ﬁnding can
be translated into clinical use will require further study; how-
ever, seeing a decline in CD4 count should raise a clinician’s
concern for the potential of increased mortality risk.
HIV RNA category was independently associated with
mortality with a consistent increase in hazard with increasing
HIV RNA. It is notable that the mortality hazard was 64%
higher for patients with even modestly elevated HIV RNA
between 400 and 4999 copies per milliliter versus ,400 cop-
ies per milliliter. Prior studies from resource-limited settings
have focused on the association between suppressed versus
nonsuppressed in assessing for associations with mortality
and have not assessed multiple gradation of viremia.23,32,33
Studies from high-income settings that have assessed for
association between gradations of HIV RNA and mortality
during cART have reported disparate ﬁndings. Several studies
found no association between HIV RNA level if CD4 count
was included in the model.38–41 Although others reported an
association between HIV RNA and either mortality, mortality
and AIDS-deﬁning illnesses, or AIDS-deﬁning illness with an
effect size of 1.0–1.8 for HIV RNA 1000–10,000 copies per
milliliter and 1.8–3.9 for HIV RNA $10,000 copies per mil-
liliter, each compared with either ,80 or ,500 copies per
milliliter.42–45 These studies did not speciﬁcally assess the
400–4999 copies per milliliter range and either identiﬁed no
or minimal association among participants with HIV RNA
between 1000 and 10,000 copies per milliliter. It is plausible
that the larger size of our study, with 3848 deaths, allowed us
to detect an association that was not found in some prior
studies. Another plausible explanation is that causes of mor-
tality in South Africa, such as tuberculosis, may be more
closely associated with HIV RNA level than causes or behav-
iors associated with mortality in Europe.13,46–48
Our estimates of CD4 change by HIV RNA level build
on prior reports. For example, studies from high-income
countries have estimated CD4 count increase among indi-
viduals on cART with suppressed HIV RNA to range from
32 to 127 cells per cubic millimeter per year4,49,50; our slope
for HIV RNA ,400 copies per milliliter of 72 cells per
cubic millimeter per year ﬁts in the middle of this range.
In addition, the variability in CD4 count change during
cART is well described.6,51
Although this study has the strength of a large dataset
generated from routine HIV care programs, it also has several
limitations. First, because we used routinely collected data,
missing data are inevitable. We used multiple imputations to
address this limitation, generating datasets with imputed
missing values for up to 17% of laboratory results. However,
multiple imputations assume that missingness can be pre-
dicted from observed variables. It is possible that individuals
were missing CD4 counts or HIV RNA values because they
were sick and at increased risk for death, in excess of what
can be predicted from other available covariates. This could
introduce bias, attenuating the observed associations with
mortality. In addition, although our dataset was large, the
number of patients contributing outcomes to speciﬁc combi-
nations of characteristics may be small and may have
contributed to the wide CIs in our adjusted model as we
observed with hazard ratio point estimates for CD4 count
slope with higher time updated CD4 counts. Although the
FIGURE 2. Absolute mortality haz-
ard from a Cox proportional hazards
model of CD4 count slope, (cells/
mm3per day), current CD4 count,
and the interaction between the 2
for a reference population of men,
aged ,24 years, with HIV RNA ,400
copies per milliliter.
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effect of uncontrolled HIV viremia on the risk of opportu-
nistic illnesses and other conditions is known, our ﬁnding of
an independent association between viremia and mortality
could be partially confounded by behaviors or circumstances
which result in both poor medication adherence and increased
risk of illness or death.
Measuring absolute CD4 count remains the cornerstone
of ART management in resource-limited settings, and our
study conﬁrms the strong association between absolute CD4
count and mortality. We have, however, described a strong
independent association between HIV RNA and mortality in
a treatment context typical of many in southern Africa and
have additionally highlighted the contribution of CD4 count
trajectory in hazard of future mortality. The next steps are to
better understand the relationships between each phenomenon
and severe illness and to identify optimal clinical and
monitoring interventions to reduce mortality among those at
highest risk.
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